Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...

In TULIP-1, anifrolumab failed to meet its objective ... An update to that study reported at the ACR this week suggests however that the drug did do better than placebo on secondary endpoints ...

A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...

A newer lupus drug can protect patients from long-term organ damage Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in ...

The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...

with few targeted biologics approved by the US Food and Drug Administration (FDA) in the last 50 years. These include GSK’s Benlysta (belimumab) and AstraZeneca’s Saphnelo (anifrolumab).

TULIP stands for ‘Treatment of Uncontrolled Lupus via the Interferon Pathway’, and the programme incorporated two studies, TULIP I and TULIP II, which evaluated the efficacy and safety of a potential ...

Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...

Lupus can do irreversible harm to a person's organs, damaging the lungs, kidneys, heart, liver and other vital organs through inflammation. But a newer lupus drug appears to protect patients from ...